DEFM14A: ESSA Pharma to be Acquired, Distributes Cash & CVRs

ESSA Pharma Inc. shareholders are invited to vote on a proposed acquisition by Xeno Acquisition Corp. for cash and contingent value rights, following the discontinuation of its clinical trials and business winding-up.

Summary

• A Special Meeting of Securityholders is scheduled for September 10, 2025, to vote on an Arrangement (acquisition) by Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, Inc., with XOMA Royalty Corporation providing assurances.
• Shareholders are proposed to receive approximately US$1.91 per Common Share in cash (reduced by any Distribution amount) plus one Contingent Value Right (CVR) for each Common Share.
• The CVR entitles its holder to a pro rata portion of up to US$2,950,000, less costs and expenses associated with any litigation against the company and its directors or officers currently active or arising within 18 months following closing of the Arrangement.
• An US$80,000,000 capital reduction and concurrent distribution to shareholders is scheduled to take place on or about August 22, 2025.
• If the Arrangement is not approved or is terminated, Securityholders will vote on a special resolution for the voluntary liquidation and dissolution of the company, and an ordinary resolution to appoint PricewaterhouseCoopers LLP (PwC) or another liquidator.
• The Board unanimously recommends voting FOR the Arrangement Resolution, Compensation Resolution, Liquidation Resolution, and Liquidator Resolution.
• The Arrangement is expected to accelerate cash payment to Securityholders, while retaining US$4,000,000 of the company's Closing Net Cash as a transaction fee.
• Following completion of the Arrangement, the company will become a private entity, delist from the Nasdaq Capital Market, and deregister under the U.S. Exchange Act.
• Leerink Partners LLC provided an oral and written opinion that the Cash Amount to be received by shareholders is fair, from a financial point of view.

Sentiment

Score: 2

Explanation: The company's primary clinical trial failed, leading to the termination of all development programs and a decision to discontinue its business. The proposed 'Arrangement' is essentially a liquidation, returning cash to shareholders, which is a negative outcome for a biotech company. The CVR offers only speculative, limited potential upside.

Positives

• The Arrangement provides certain and immediate value and liquidity to shareholders through a cash payment and potential additional value from CVRs.
• The transaction is expected to maximize and accelerate the distribution of cash to securityholders compared to a statutory liquidation process.
• The Arrangement is not subject to a financing condition, and XOMA Royalty Corporation (XRC) has unconditionally and irrevocably guaranteed the Purchaser's obligations.
• The CVRs offer an opportunity for shareholders to receive a pro rata portion of up to US$2,950,000 from resolved litigation and other liabilities.
• The likelihood of completing the Arrangement is considered high due to the lack of required material regulatory filings and specific, limited closing conditions.
• The Board retains the ability to respond to superior acquisition proposals and change its recommendation, subject to certain conditions and a termination payment.
• Registered shareholders have dissent rights, allowing them to seek fair value for their shares if they oppose the Arrangement.

Negatives

• The company terminated its Phase 2 clinical trial for masofaniten (EPI-7386), its primary molecule, and is discontinuing all clinical and preclinical development programs, indicating a failure of its core business strategy.
• All outstanding stock options are currently expected to be 'out-of-the-money' at the Effective Time, meaning optionholders will receive no payment for them.
• The CVRs are contractual rights only, non-transferable (except in limited circumstances), and will not be listed on any securities exchange, limiting liquidity and certainty of value.
• The CVR payment is contingent on the outcome of litigation and other liabilities, and holders may receive no proceeds if associated costs and expenses exceed US$2,950,000.
• Certain directors and executive officers have interests in the Arrangement that differ from general securityholders, including change-in-control payments and indemnification.
• The Arrangement or subsequent liquidation will generally be a taxable transaction for most shareholders, potentially leading to adverse U.S. federal income tax consequences due to the company's expected classification as a Passive Foreign Investment Company (PFIC).
• A US$4,000,000 transaction fee will be retained by the Purchaser from the company's cash balance.
• A contingent reserve of US$3,700,000 is set aside for company litigation, which reduces the cash available for distribution.

Risks

• There is no certainty that all conditions precedent to the Arrangement will be satisfied, including required securityholder and court approvals.
• If the Arrangement is not completed or is materially delayed, the market price of the Common Shares may be adversely affected.
• The Agreement may be terminated in certain circumstances, potentially requiring the company to pay a US$2,500,000 Termination Payment to the Purchaser.
• The dedication of substantial company resources to the Arrangement could negatively impact the company's assets, results of operations, or prospects if the transaction is not completed.
• Directors and officers of the company have interests in the Arrangement that may be different from those of securityholders generally.
• The Purchaser and the company may be targets of legal claims, securities class actions, derivative lawsuits, and other claims, which could incur substantial costs and delay or prevent the Arrangement.
• The relative trading price of the Common Shares prior to the Effective Date may be volatile.
• Securityholders will no longer have any rights or interest in the company following the completion of the Arrangement.
• The Arrangement or the Liquidation may result in a tax payable for shareholders, and adverse U.S. federal income tax consequences due to the company's expected classification as a PFIC.
• The Termination Payment may discourage other parties from attempting to acquire the company.
• Holders of the CVRs may never receive any proceeds if company litigation expenses exceed US$3,550,000.
• The CVRs will not be listed on any exchange and are non-transferable, limiting the ability to realize their value prior to the CVR Payment Date.
• The U.S. federal income tax treatment of CVRs is unclear, leading to uncertainty regarding the amount, timing, and character of any gain, income, or loss.
• The Canadian federal income tax treatment of CVRs is unclear.
• If the Liquidation proceeds, the company cannot assure shareholders of the timing or amount of any distributions, which may be substantially less than expected.
• The company will continue to incur expenses during liquidation, including public company reporting costs and service provider fees, which will reduce the amount available for distribution.
• Shareholders receiving liquidation distributions could be liable for payment to the company's creditors if the company fails to retain sufficient funds to cover liabilities.

Future Outlook

The company intends to discontinue and wind up its business, having terminated all clinical trials and preclinical development programs. It does not have a standalone business plan. Following the Arrangement, the company will become a private entity, delist from Nasdaq, and deregister under the U.S. Exchange Act, ceasing all public reporting obligations. If the Arrangement is not consummated, and the Liquidation Resolution is approved, the company will proceed with a voluntary liquidation and dissolution. The timing and amount of any future liquidation distributions are uncertain and may be delayed or result in less value than currently estimated.

Management Comments

• "We look forward to seeing you at the meeting." David R. Parkinson, President, Chief Executive Officer and Director.
• The Board and Transaction Committee unanimously determined that the Consideration to be received by the Securityholders pursuant to the Arrangement is fair, from a financial point of view, to the Securityholders, and that the Arrangement is in the best interests of the Company.
• The company believes that the Consideration to be paid to the Securityholders in the Arrangement is more favorable than the potential value from a statutory liquidation, citing reduced operating costs and earlier cash distribution.

Industry Context

The company, a clinical-stage pharmaceutical firm focused on prostate cancer therapies, is undergoing a complete business discontinuation following the termination of its primary clinical trial (masofaniten, EPI-7386) due to a lack of clear efficacy benefit. This move reflects a challenging biotech market where clinical failures often lead to asset liquidation rather than continued development or reverse mergers. The acquisition by Xeno Acquisition Corp., backed by biotech royalty aggregator XOMA Royalty Corporation, highlights a shift towards monetizing remaining cash and intellectual property rather than pursuing further drug development, aligning with a financial exit strategy in a difficult funding environment for early-stage biotechs.

Comparison to Industry Standards

• The termination of the Phase 2 clinical trial for masofaniten (EPI-7386) due to a lack of clear efficacy benefit compared to standard of care (enzalutamide monotherapy) indicates a worse-than-expected outcome for a drug candidate in a competitive therapeutic area like mCRPC.
• The decision to pursue a cash acquisition and liquidation, rather than a reverse merger, suggests that the company and its advisors assessed the prevailing public market conditions and the ability to secure PIPE financing for reverse mergers as unfavorable, indicating a challenging environment for biotech companies with failed clinical programs.
• The implied estimated present value of dissolution payments (US$1.86 per Common Share) compared to the assumed value of the Cash Amount plus Distribution (US$1.91 per Common Share) suggests the Arrangement offers a slightly better, more immediate return than a prolonged statutory liquidation, which is a common consideration for companies in this situation.

Management Changes

Corporate Governance

Legal Proceedings

• Shareholder putative class litigation filed on January 24, 2025, in the United States District Court for the Eastern District of Wisconsin (Van Groll v. ESSA Pharma, et al., Case No. 1:25-cv-00124-WCG) against the company and individual defendants, alleging material misstatements and/or omissions regarding clinical trials.
• A contingent reserve of US$3,700,000 is set aside for any Company Litigation, which includes the aforementioned class action lawsuit.
• The CVRs' potential payout is reduced by costs and expenses associated with any litigation against the company and its directors or officers currently active or arising within 18 months following closing of the Arrangement, with a specific allocation of up to US$2,800,000 for legal expenses.

Related Party Transactions

• David Parkinson (President, CEO, and Director) is entitled to a collateral benefit of US$303,849 (Change of Control Payment), which is 241.90% of his expected share consideration (US$125,611.15). His 65,765 Common Shares (0.001% of outstanding) will be excluded from the minority approval vote.
• David Wood (Chief Financial Officer) is entitled to a collateral benefit of US$225,716 (Change of Control Payment), which is 354.42% of his expected share consideration (US$63,685.13). His 33,343 Common Shares (0.0008% of outstanding) will be excluded from the minority approval vote.
• XOMA Royalty Corporation (XRC) will receive a US$3,000,000 fee from Parent (XenoTherapeutics, Inc.) for services rendered in identifying, referring, or introducing prospective targets culminating in a successful transaction.

Stakeholder Impact

• **Shareholders**: Will receive a cash payment (approx. US$1.91 per share, reduced by Distribution) and CVRs (potential for up to US$2,950,000 less litigation costs). They will lose their equity ownership and voting rights in a public company and face tax consequences from the transaction.
• **Optionholders/Warrantholders**: In-the-money options/warrants will receive cash (Cash Amount minus exercise price) and one CVR. Out-of-the-money options/warrants will be cancelled without payment.
• **Employees**: Several executive officers' employment terminated prior to the Arrangement. Remaining employees involved in the Discontinuance may be incentivized to stay through the liquidation process. Named executive officers are eligible for severance and change-in-control payments.
• **Creditors**: The company will satisfy all valid creditor claims and set aside reserves for contingent claims during the liquidation process. There is a potential risk of shareholder liability for payment to creditors if the company fails to retain sufficient funds.
• **Management/Directors**: Will receive change-in-control payments and continued indemnification/insurance. Members of the newly formed CVR Committee (two former directors) will receive US$25,000 each for their service.

Next Steps

• Special Meeting of Securityholders on September 10, 2025, to vote on the Arrangement Resolution, Compensation Resolution, Liquidation Resolution, and Liquidator Resolution.
• If the Arrangement Resolution is approved, the company will apply for a Final Order from the Supreme Court of British Columbia (expected September 12, 2025).
• Assuming the Final Order is granted, the Arrangement is expected to complete on or about September 18, 2025.
• Following completion of the Arrangement, the company will apply to cease being a reporting issuer in Canada, delist from Nasdaq, and deregister under the U.S. Exchange Act.
• The Purchaser will undertake a voluntary dissolution of the company pursuant to Section 314 of the BCBCA.
• If the Arrangement Resolution is not approved or terminated, and the Liquidation Resolution is approved, the company will proceed with voluntary liquidation and dissolution, appointing PwC or another liquidator.
• If liquidation proceeds, a Court-approved Claims Process will be established, and any remaining assets will be distributed to shareholders after satisfying liabilities.

Key Dates

Recommendation

The company's core drug development programs have failed, leading to a strategic decision to discontinue its business and liquidate. The proposed 'Arrangement' is essentially a cash-out event for shareholders, offering a fixed cash amount and a highly speculative CVR. Given the failure of the underlying business, the delisting, and the non-transferable nature of the CVRs, a seasoned investor would likely view this as an exit opportunity to realize the offered cash value and avoid the uncertainties and illiquidity associated with the CVR and the eventual dissolution. The stock price on July 11, 2025 (US$1.71) was below the estimated cash consideration (US$1.91), suggesting an immediate upside for shareholders to sell into the acquisition.

Keywords

ESSA Pharma Inc., Xeno Acquisition Corp., XenoTherapeutics, Inc., XOMA Royalty Corporation, Arrangement, Acquisition, Liquidation, Contingent Value Right (CVR), Biotech, Pharmaceutical, Prostate Cancer, Clinical Trials Termination, SEC Filing, DEFM14A, Shareholder Vote, Delisting, Deregistration, Cash Distribution, Corporate Governance, Risk Factors, Tax Implications